



Applied Genetic Technologies Corporation
Investor Relations Department
14193 NW 119th Terrace
Suite 10
Alachua, FL 32615
United States

[Visit IR website](#) 
[Sign-up for email alerts](#) 

NASDAQ: AGTC

Last Trade:	3.75
Trade Time:	4:00 PM ET Sep 19, 2017
Change:	0.00 (0.000%)
Day Range	3.65 - 3.90
52-Week Range	3.50 - 10.85
Volume	261,232

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's lead product candidates focus on inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments.

AGTC's product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis (XLRS), X-linked r... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Sep 13, 2017*
[AGTC Announces Financial Results and Business Update for the Quarter and Fiscal Year Ended June 30, 2017](#)
- Sep 5, 2017*
[AGTC Appoints Matthew Feinsod, M.D. as Interim Chief Medical Officer](#)
- Aug 31, 2017*
[AGTC to Host Fourth Quarter and Fiscal Year Financial Results Conference Call and Webcast on September 13, 2017](#)
- Aug 15, 2017*
[AGTC and the Foundation Fighting Blindness Announce Partnership Agreement](#)
- Aug 10, 2017*
[AGTC Files Investigational New Drug Application for the Treatment of X-linked Retinitis Pigmentosa Caused by Mutations in the RPGR Gene](#)

Financials [\[View all \]](#)

- Sep 13, 2017*
[Annual Report \(10-K\)](#)
- Jan 13, 2017*
[Proxy Statement \(DEF 14A\)](#)
- May 10, 2017*
[Quarterly Report \(10-Q\)](#)
- Feb 8, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 8, 2016*
[Quarterly Report \(10-Q\)](#)